Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1588739rdf:typepubmed:Citationlld:pubmed
pubmed-article:1588739lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:1588739lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1588739lifeskim:mentionsumls-concept:C0003211lld:lifeskim
pubmed-article:1588739lifeskim:mentionsumls-concept:C1518422lld:lifeskim
pubmed-article:1588739lifeskim:mentionsumls-concept:C0003212lld:lifeskim
pubmed-article:1588739pubmed:issue3lld:pubmed
pubmed-article:1588739pubmed:dateCreated1992-6-25lld:pubmed
pubmed-article:1588739pubmed:abstractTextNon-steroidal anti-inflammatory drugs (NSAIDs) are often prescribed to patients with rheumatoid arthritis (RA), as the first line drugs, and are administered over a long term. NSAIDs are classified principally into acidic and basic preparations, and the former is more widely used for the treatment, since the latter possesses no anti-rheumatic effect. Moreover, the acidic NSAIDs are classified into salicylates, arylacetic acid, pyrazolone, fenamates and oxicams. Arylacetic acid has a strong analgesic effect. Pyrazolone is well balanced between analgesic, anti-inflammatory and antifebrile effects. The fenamates and oxicams are long acting. On the other hand, NSAIDs sometimes inhibit adverse reactions, such as gastroduodenal diseases and renal insufficiency, which are probably induced by the inhibition of cyclo-oxygenase to reduce prostaglandin content. Therefore, appropriate NSAIDs must be selected after consideration on the character, property and adverse reaction of each drug.lld:pubmed
pubmed-article:1588739pubmed:languagejpnlld:pubmed
pubmed-article:1588739pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1588739pubmed:citationSubsetIMlld:pubmed
pubmed-article:1588739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1588739pubmed:statusMEDLINElld:pubmed
pubmed-article:1588739pubmed:monthMarlld:pubmed
pubmed-article:1588739pubmed:issn0047-1852lld:pubmed
pubmed-article:1588739pubmed:authorpubmed-author:ItoYYlld:pubmed
pubmed-article:1588739pubmed:authorpubmed-author:NakagawaTTlld:pubmed
pubmed-article:1588739pubmed:authorpubmed-author:YanagawaAAlld:pubmed
pubmed-article:1588739pubmed:authorpubmed-author:YukinariTTlld:pubmed
pubmed-article:1588739pubmed:issnTypePrintlld:pubmed
pubmed-article:1588739pubmed:volume50lld:pubmed
pubmed-article:1588739pubmed:ownerNLMlld:pubmed
pubmed-article:1588739pubmed:authorsCompleteYlld:pubmed
pubmed-article:1588739pubmed:pagination509-14lld:pubmed
pubmed-article:1588739pubmed:dateRevised2011-7-27lld:pubmed
pubmed-article:1588739pubmed:meshHeadingpubmed-meshheading:1588739-...lld:pubmed
pubmed-article:1588739pubmed:meshHeadingpubmed-meshheading:1588739-...lld:pubmed
pubmed-article:1588739pubmed:meshHeadingpubmed-meshheading:1588739-...lld:pubmed
pubmed-article:1588739pubmed:year1992lld:pubmed
pubmed-article:1588739pubmed:articleTitle[NSAIDs (non steroidal anti-inflammatory drugs) for the treatment of rheumatoid arthritis].lld:pubmed
pubmed-article:1588739pubmed:affiliationInstitute of Medical Science, St. Marianna University School of Medicine.lld:pubmed
pubmed-article:1588739pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1588739pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:1588739pubmed:publicationTypeReviewlld:pubmed